menu
    • menu
    [{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Collagen","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cayman Chemical Company Inc \/ NIDCR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Chemical Company Inc \/ NIDCR"},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"SBIR","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Antibody","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cayman Chemical Company Inc \/ SBIR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Chemical Company Inc \/ SBIR"},{"orgOrder":1,"company":"Cayman Pharma s.r.o","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CZECH REPUBLIC","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"KMN-159","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Pharma s.r.o","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Cayman Pharma s.r.o \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Pharma s.r.o \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cayman Pharma s.r.o

    Menu

    Cayman Pharma s.r.o

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cayman Pharma s.r.o

                            Czech Republic
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothCayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

                            Lead Product(s) : KMN-159

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cayman Update on its Dental Implant candidate KMN-159 for Osseointegration

                            Details : KMN-159 is a potent, stable, and a highly selective EP4 receptor agonist that stimulates osteogenic activity. It is being evaluated for the treatment of osteoporosis.

                            Brand Name : KMN-159

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2023

                            Lead Product(s) : KMN-159

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Cayman

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cayman Chemical Company Inc

                            U.S.A
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KMN-159,Collagen

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : NIDCR

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration

                            Details : The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.

                            Brand Name : KMN-159

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 16, 2021

                            Lead Product(s) : KMN-159,Collagen

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : NIDCR

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            Cayman

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cayman Chemical Company Inc

                            U.S.A
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : SBIR

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cayman Receives SBIR Grant for Alzheimer’s Research

                            Details : The funding will be used to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 08, 2020

                            Lead Product(s) : Antibody

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : SBIR

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            Cayman

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth